RxDoctor Payments Data

Tarun Jain, MD

Interventional Cardiology · Kankakee, ILNPI 1316289077

Payments from drug & device makers

$11,303in general payments, 2019–2025

Across 264 payments — averaging $42.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novartis$2K
  • Abiomed$2K
  • Medtronic$2K
  • Johnson & Johnson$570
  • E.r. Squibb & Sons, L.L.C.$418
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$1,63514%
  • Travel & lodging$2,30720%
  • Food & beverage$7,23964%
  • Education$1221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,303 in reported general payments places this provider in the 55th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$297,163
Medicare patients
1,663
Services billed
4,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban384$437,213
EntrestoSacubitril/Valsartan105$142,440
JardianceEmpagliflozin82$106,543
FarxigaDapagliflozin Propanediol85$89,858
XareltoRivaroxaban71$82,975
Repatha SureclickEvolocumab70$51,458
BrilintaTicagrelor70$38,617
Praluent PenAlirocumab34$17,572
VascepaIcosapent Ethyl18$15,485
Metoprolol Succinate686$9,771
Atorvastatin Calcium683$6,975
Ezetimibe182$6,043
Losartan Potassium555$4,972
ClopidogrelClopidogrel Bisulfate394$4,702
Amiodarone Hcl98$3,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$437,213384 claims
NovartisEntresto$2,201$142,440105 claims
AstraZenecaFarxiga, Brilinta$103$128,474155 claims
Boehringer IngelheimJardiance$32$106,54382 claims
Johnson & JohnsonXarelto$570$82,97571 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Kankakee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →